With the recent proliferation of treatment options for patients with follicular lymphoma (FL),
median survival has been shown to have improved, from 84 months between 1983 and …

Background Follicular lymphoma is the second most common non-Hodgkin lymphoma in the
United States and Europe. However, most of the prospective randomized studies have very …

Although autologous stem cell transplantation (ASCT) can achieve durable responses in
eligible patients with follicular lymphoma (FL), long‐term follow‐up is needed to determine if …

Follicular lymphoma (FL) is an incurable but treatable disease with vast treatment options.
Despite the abundance of efficacious treatment modalities, there is no universally agreed …

Background Follicular lymphoma (FL) is a common form of non-Hodgkin lymphoma with a
wide spectrum of presentation. While grade 1/2 FL is considered low grade and grade 3B FL …

Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall
survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 …

Purpose: To determine, in a randomized clinical trial, whether high-dose therapy (HDT)
followed by autologous stem-cell transplantation is more effective than standard treatment …

Follicular lymphoma (FL) originates from germinal center B cells, is the most prevalent form
of indolent non-Hodgkin's lymphoma. Upfront management is based on stage, grade, and …

Purpose In low–tumor burden follicular lymphoma (FL), maintenance rituximab (MR) has
been shown to improve progression-free survival when compared with observation. It is not …

Abstract 427 Rituximab is effective as single agent therapy in the treatment of follicular
lymphoma (FL), and when combined with chemotherapy has extended remissions and …